Predict your next investment

Venture Capital
dhventures.de

See what CB Insights has to offer

Investments

5

Portfolio Exits

2

About Digital Health Ventures

Digital Health Ventures (DHV) is a venture capital fund specializing in early stage startups Digital Health.

Digital Health Ventures Headquarter Location

Gormannstr. 14

Berlin, 10119,

Germany

+49 (0)30 720 24 994

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Digital Health Ventures News

Implandata Wins Medica Innovation World Cup – 1st Place of 300 Digital Health Ventures

Dec 1, 2021

Implandata Wins Medica Innovation World Cup – 1st Place of 300 Digital Health Ventures HANNOVER, Germany and SAN DIEGO, USA, December 01, 2021 / B3C newswire / -- Implandata Ophthalmic Products , a digital eye care company based in Germany and USA, was awarded 1st place at the Healthcare Innovation World Cup at MEDICA , the world’s largest medical trade fair. In an intense competition, with 300 healthtech companies from 60 countries, Implandata and its disruptive EYEMATE™ system were recognized by the expert jury as the top digital health solution based on the level of innovation, go-to-market-approach, commercial potential and sustainability. Max Ostermeier, CEO and founder of the company states: “The Implandata team is very excited and proud to win this prestigious award. It confirms the high degree of innovation of our EYEMATE system, and the huge market opportunity it addresses.” Dominick Arena, Chairman of the company says: “Implandata is currently preparing the European market launch of the EYEMATE system and has started the US market FDA approval process. The company will build a strong business foundation on the sales of EYEMATE biosensors and recurring revenues for remote patient monitoring and therapy guidance services.” Investors value the MEDICA Innovation World Cup, a premier venue for companies that are transforming healthcare. Remote patient monitoring and telehealth are a key focus, as they are powering the transformation of chronic disease management, including the $6B glaucoma care market. For high resolution please click the image. About Glaucoma – the leading cause of irreversible, debilitating vision loss worldwide 80 million people with the chronic eye disease glaucoma suffer the risk of permanently losing vision, eventually going blind. Current practice (typically 4 office visits/year) is insufficient to prevent vision loss for many patients. Glaucoma status between visits is unknown. Though doctors have many treatment options, delayed detection of disease progression delays therapy adjustment and results in further loss of eyesight. EYEMATE is the world’s only CE-marked, clinically-validated system for remote glaucoma care. Implandata’s patented biosensors and cloud-based, AI-system alert patients and their eye doctor in real-time of uncontrolled glaucoma. When the disease progresses, EYEMATE enables the therapy to be adjusted immediately – before the patient loses further vision Implandata, based in Germany/USA, is a digital health & medical device company dedicated to improving the lives of millions of people with glaucoma. Breakthroughs in biosensing, telemetry and data analytics led to the EYEMATE system. The CE-marked EYEMATE system is in use at leading eye centers in Europe. In the US market, EYEMATE has obtained the FDA “Breakthrough Device Designation”. In China, EYEMATE is ready to start the NMPA approval process.

Digital Health Ventures Investments

5 Investments

Digital Health Ventures has made 5 investments. Their latest investment was in Wefight as part of their Series A on September 9, 2021.

CBI Logo

Digital Health Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/14/2021

Series A

Wefight

$11.83M

Yes

4

3/15/2019

Series A

Subscribe to see more

$99M

Subscribe to see more

10

11/18/2017

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

10/24/2017

Unattributed VC

Subscribe to see more

Subscribe to see more

10

6/20/2016

Seed VC

Subscribe to see more

Subscribe to see more

10

Date

9/14/2021

3/15/2019

11/18/2017

10/24/2017

6/20/2016

Round

Series A

Series A

Seed VC

Unattributed VC

Seed VC

Company

Wefight

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$11.83M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

10

10

10

10

Digital Health Ventures Portfolio Exits

2 Portfolio Exits

Digital Health Ventures has 2 portfolio exits. Their latest portfolio exit was Teleclinic on July 16, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/16/2020

Acquired

$99M

9

12/3/2018

Asset Sale

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/16/2020

12/3/2018

Exit

Acquired

Asset Sale

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Sources

9

10

Digital Health Ventures Team

2 Team Members

Digital Health Ventures has 2 team members, including current Managing Partner, Guido Hegener.

Name

Work History

Title

Status

Guido Hegener

XLHEALTH

Managing Partner

Current

Ulli Jendrik Koop

XLHEALTH

Managing Partner

Current

Name

Guido Hegener

Ulli Jendrik Koop

Work History

XLHEALTH

XLHEALTH

Title

Managing Partner

Managing Partner

Status

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.